|
|
|
|
|
|
|
|
|
|
|
12.11.26 - 00:06
|
Zocdoc Brings AI to Healthcare (Bloomberg)
|
|
|
AI agents are moving into health care, taking on tasks from finding an in-network doctor to booking appointments around a patient's schedule. Zocdoc CEO Oliver Kharraz says traffic to the platform from AI agents has grown nearly 30-fold since July and has been doubling roughly every 10 days since early September. He joins Bloomberg Businessweek Daily to discuss how the company is openings its doors to AI while keeping patient privacy intact. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11.26 - 20:18
|
Google′s Gemini Targets Health Care′s Data Problem (Bloomberg)
|
|
|
Google Cloud is launching Gemini for Health Care, an AI platform designed to connect fragmented information across hospitals, insurers and other health systems while reducing administrative work. Aashima Gupta, Global Leader of Healthcare at Google Cloud, discusses how Gemini can connect medical records, clinical guidelines and business systems, and how Google is building privacy, security and HIPAA compliance into the platform. She joins Riley Griffin on "Bloomberg Tech." (Source: Bloomberg)...
|
|
|
|
|
10.11.26 - 16:48
|
Linnemann: Pharma-Standortpolitik nicht mit Beitragsgeldern (DPA-AFX)
|
|
|
BERLIN (dpa-AFX) - Bundesgesundheitsminister Carsten Linnemann befürwortet Preisvorteile für Arzneimittelhersteller mit Produktion und Investitionen in Deutschland, aber nicht auf Kosten der gesetzlichen Krankenkassen. "Standortpolitik müssen wir natürlich ......
|
|
|
|
|
|
|
10.11.26 - 14:18
|
Pharma firms′ focus on weight-loss drugs could put insulin supply at risk, experts warn (The Guardian)
|
|
|
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms' attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.GLP-1 blockbuster medications such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group. Continue reading......
|
|
|
10.11.26 - 11:54
|
Hims & Hers Health unter Druck: Enttäuschende Quartalszahlen und Margenverfall belasten die Aktie (Investing.com DE)
|
|
|
Die Aktie von Hims & Hers Health gibt im vorbörslichen Handel um 3,7 % auf 22,10 $ nach und setzt damit ihre Kursverluste fort, die am Montagabend nach Veröffentlichung enttäuschender Ergebnisse für das dritte Quartal 2026 einsetzten. Das Telemedizin-Unternehmen rutschte mit einem Nettoverlust von 0,14 $ je Aktie in die roten Zahlen und verfehlte damit den Analystenkonsens, der ein positives Ergebnis von 0,06 $ je Aktie erwartet hatte, deutlich. Der Umsatz legte im Jahresvergleich zwar um 49 % auf 890,4 Millionen $ zu, blieb jedoch knapp hinter den Markterwartungen von rund 892,9 Millionen $ zurück..
|
|
|
10.11.26 - 05:00
|
Chinese biotech giant WuXi AppTec′s shares jump after Pentagon blacklist reversal (SCMP)
|
|
|
WuXi AppTec's shares jumped on Tuesday after the Pentagon removed the company from a list of entities allegedly linked to the Chinese military, marking a win for the biotech service giant and raising hopes among other mainland firms challenging US blacklists.
The US deputy secretary of defence decided to delist WuXi AppTec from its list of “Chinese military companies”, according to a notice published on the Federal Register on Tuesday.
WuXi AppTec surged more than 6 per cent at the open in Hong......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
